Monster Beverage Shorts Pile In Before November Print

Options positioning has also tilted more cautious than usual, though not dramatically so. The put/call ratio has climbed to 0.76, above its 20-day average of 0.67 and roughly 1.3 standard deviations above that mean. That's not an extreme reading, the 52-week high on the PCR sits at 1.74, but the directional shift over the past two weeks is clear: the PCR ran between 0.57 and 0.59 in late September and has stepped higher every week since. Taken together with the short interest build, the positioning tells a cautious story rather than a panicked one.

The Street adds context to why bears are gaining conviction. Wells Fargo's Chris Carey cut his price target to $48 from $53 on October 5, maintaining his Overweight rating, making it the most recent and most relevant analyst move. That target sits 11% above the current price of $43.31, implying the market is pricing in more downside risk than the bullish camp allows for. Prior to the Wells Fargo trim, analysts lifted targets broadly in August after the last quarterly print, with firms including RBC, Piper Sandler and Evercore all raising to around $100 to $105. Those targets are far above the current share price, a gap that creates a data-consistency concern: the stock has fallen sharply since those August revisions, and the mean price target across the analyst universe sits at $50. The August-vintage targets likely reflect a stock that was trading materially higher before what the earnings history describes as a severe five-day decline. The August 6 print produced a single-day loss of 4.3% and a five-day loss of 50.6%, which is the most significant data point in this note. MNST has not recovered that ground, and the stock is now down about 1% on the day and essentially flat on the week at $43.31.

The bull case rests on international momentum. Bulls point to 20% net sales growth, 35% international sales growth, and early-stage penetration across Brazil, India and China as evidence that the growth engine is intact. The Coca-Cola distribution relationship remains a structural tailwind, and gross margins expanded to 55.9% last quarter. The bear case is centred on cost pressure: selling expenses are running at 10.6% of net sales versus 9.3% a year ago, distribution costs are up too, and management guided to continued modest sequential increases in aluminum costs through at least the end of 2026. Selective Q4 pricing in the US may not fully offset that pressure. On valuation, MNST trades at 34 times earnings and 25 times EV/EBITDA. Both multiples have edged lower over the past 30 days, and the EV/EBIT factor score ranks in just the 11th percentile of the universe, reflecting a premium price for a business whose near-term profit trajectory is under pressure.

One structural footnote worth noting: Coca-Cola holds a 21% stake in Monster, as disclosed in a Schedule 13D/A filing in January 2025. That relationship underpins the bull case on distribution, but the 13D classification flags it as an activist-category position on the SEC register. Per the standard disclosure caveat, the 21% figure is as last disclosed and stakes can move without a fresh filing below the 5% threshold. ORTEX also forecasts a 25% probability that MNST could be added to the CRSP US Mid index at the December 2026 quarterly review, with $765 million of tracker buying implied if that were to happen. The stock would need to close above $38.05 to qualify. At $43.31, it is already above that level, so the qualification bar is not the constraint here; the 25% probability reflects broader uncertainty in the ranking.

With the next print 22 days out, the question that will settle is whether the Q3 numbers show margin stabilisation or a further squeeze from cost inflation, and whether international volume growth is strong enough to absorb the operating expense build.